Anti-Tac for Treatment of Leukemia

NCT00001941 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

HTLV-I Infection
T Cell Leukemia

Interventions

BIOLOGICAL: daclizumab

Sponsor

National Cancer Institute (NCI)